Wolverine Asset Management’s Sinovac Biotech SVA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q4
– Sell
-99,212
Closed -$699K – 1750
2017
Q3
$699K Buy
99,212
+20,342
+26% +$139K 0.01% 758
2017
Q2
$532K Buy
+78,870
New +$432K 0.01% 767

Other funds holding SVA

Wolverine Asset Management's SVA Position: Q4 2017 in Review

Wolverine Asset Management sold out of Sinovac Biotech (SVA) in Q4 2017, closing a stake of 99,212 shares — an estimated $699K sold.

Wolverine Asset Management first reported a position in SVA in Q2 2017 and held it in 2 quarters. The position peaked at $699K in Q3 2017. 31 funds tracked by Wall St. Rank hold SVA as of Q4 2017.

  • Wolverine Asset Management reported no remaining Sinovac Biotech position as of Q4 2017 after selling out during the quarter.
  • Wolverine Asset Management sold 99,212 Sinovac Biotech shares in Q4 2017, an estimated $699K.
  • Wolverine Asset Management first reported a position in Sinovac Biotech in Q2 2017 and held it in 2 quarters.
  • Wolverine Asset Management's Sinovac Biotech position peaked at $699K in Q3 2017.
  • 31 funds tracked by Wall St. Rank held Sinovac Biotech as of Q4 2017.

Based on Wolverine Asset Management's 13F filing for Q4 2017, filed 14 Feb 2018.